Verve Therapeutics
NASDAQ: VERV
Developing treatments for cardiovascular diseases though gene-editing.
Developing treatments for cardiovascular diseases though gene-editing.
Sector
Life SciencesCategory
TherapeuticsLocation
Cambridge, MAInitial Investment
2019Verve Therapeutics (NASDAQ: VERV) is a biotechnology company created with a singular focus: to protect the world from heart disease. Verve is developing therapies to safely edit the genome of adults and confer lifelong protection from coronary artery disease, the most common form of heart disease and the leading cause of death worldwide.
“F-Prime stood with us as we charted new territory—from reimagining the treatment of heart disease to advancing one of the first in vivo base editing programs in the clinic. Their support was instrumental in getting us from bold idea to clinical reality.”
Sekar Kathiresan, Co-founder & CEO